On 10^th November 2022. Hong Kong China. The second “Asia Summit on Global Health” (ASGH) was staged grandly at the Hong Kong Convention and Exhibition Centre by the Hong Kong Government and Hong Kong Trade Development Council. The summit was themed “Charting a New Course in Healthcare through Collaboration”, bringing together healthcare experts and key industry players to exchange insights about the opportunities and developments of Hong Kong healthcare industry etc.

 
Li Ka Chiu—CE of HKSAR attended the summit and stated that the future development of Hong Kong healthcare includes 3 aspects: firstly, promoting the development of healthcare innovation; secondly, attracting talents to ensure the sustainable development of healthcare industry, Hong Kong will switch the focus of healthcare from treatment to prevention and community-centered.
Vice director of The National Health Commission--Mr. Cao Xue Tao and Deputy Director-General of WHO—Dr. Zsuzsanna Jakab also gave a speech through online respectively.
 
Song Rui Lin—President of China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Director of ZSHK was invited to participate in the plenary session themed “Charting a New Course in Healthcare through Collaboration” of the summit to discuss different collaboration directions of global healthcare industry and shared his opinions about the way to construct a more resilient, sustainable and harmonized future. President Song pointed out that China’s revolution on the system of drug evaluation in 2015 has contributed to the rapid development of China pharmaceutical industry. China pharmaceutical innovation could not stand without the world, the world could not stand without China either. After the National Medical Products Administration (NMPA)’s joining to ICH in 2017, relevant monitoring and instruction principles are gradually being implemented. China pharmaceutical innovation is actively stepping into the global stage, promoting the further development of global pharmaceutical industry, contributing collaboratively to human health all around the world.
   
During the panel discussion of “The Next Development of China’s Healthcare Sector”, Dr. Li Ming—CEO of ZSHK shared his opinions about the opportunities for development of Hong Kong innovation and technology enterprise in the Greater Bay Area. Dr. Li mentioned that Hong Kong backs the motherland, has great market development and prospect. At the same time, owns huge number of talents with excellent academic qualifications, mature financial and law service industry that has given a good development foundation for the pharmaceutical innovation. Hong Kong, as the high ground of pharmaceutical innovation, should focus on early-stage innovation research and translation and should strengthen the interaction between basic research and clinical treatment, specifically exploit unsatisfied demands of clinical treatment for now to elevate Hong Kong’s ability of innovation and technology. At the same time, recommending the government could increase investment on early-stage research and translation to promote biopharmaceutical innovation of Hong Kong together with social capitals.